Discover 3 Stocks That May Be Trading Below Their Estimated Value

Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy

Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases

Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases

TVTX Stock Slides 6% On Everest Deal, Erases Some Losses As Analyst Sees 49% Upside

3 Stocks That May Be Priced Below Their Estimated Worth In June 2026

Extreme Networks And 2 Other Stocks That Could Be Trading Below Their Estimated Value

Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress

3 Stocks That May Be Priced Below Their Estimated Value In June 2026

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)